

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for the treatment of gastrointestinal disorders comprising the administration of an aqueous suspension via a gastric tube to a pediatric patient in need of such treatment, wherein:
 - the aqueous suspension comprises a solid composition dispersed in an aqueous carrier;
 - the solid composition comprises a therapeutically effective amount of an acid labile proton pump inhibitor in the form of a multiple of enteric coating layered pellets in admixture with one or more pharmaceutically acceptable thickeners **selected from the group consisting of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin, and combinations thereof;** and
 - the viscosity of the aqueous suspension is 0.05 Pa s or greater, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
2. (Canceled)
3. (Original) The method according to claim 1, wherein the thickener is selected from starch and xanthan gum.
4. (Previously presented) The method according to claim 1, wherein the solid composition further comprises one or more pharmaceutically acceptable additives selected from the group consisting of flavouring agents, colour agents and sweetening agents.
5. (Canceled)

6. (Withdrawn) The method according to claim 5, wherein the viscous aqueous medium is selected from the group consisting of yoghurt, sour milk, and syrup.
7. (Withdrawn) The method according to claim 5, wherein the viscous aqueous medium is a sugar syrup with a sugar content of at least 63% by weight.
8. (Currently amended)) The method according to claim 1 [[or 5]], wherein the viscosity of the aqueous suspension is in the range of from 0.05 to 10 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
9. (Currently amended) The method according to claim 1 [[or 5]], wherein the viscosity of the aqueous suspension is in the range of from 0.05 to 5 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
10. (Currently amended) The method according to claim 1 [[or 5]], wherein the gastric tube has a size in the range of from CH 5 to CH 10 (CH= Cherrier).

Claim 11 (Canceled)

12. (Currently amended) The method according to claim 1 [[or 5]], wherein the proton pump inhibitor compound is selected from the group consisting of omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, esomeprazole and a pharmaceutically acceptable salt thereof.
13. (Currently amended) The method according to claim 1 [[or 5]], wherein the amount of proton pump inhibitor compound that is administered is in the range from 0.5 to 40 mg.
14. (Withdrawn) The method according to claim 1, wherein the aqueous carrier is selected from the group consisting of water, fruit juice, syrup and dairy products.

15. (Previously presented) The method according to claim 1, wherein the amount of aqueous carrier is in the range from 1 to 35 mL.

16. (Currently amended) A pharmaceutical formulation for administration through a gastric tube to a pediatric patient, wherein:

- the pharmaceutical formulation is in the form of an aqueous dispersion comprising a solid composition dispersed in an aqueous carrier;
- the solid composition comprises a proton pump inhibitor in the form of a multiple of enteric coating layered pellets in admixture with one or more pharmaceutically acceptable thickeners **selected from the group consisting of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin, and combinations thereof**; and [[.]]
- the viscosity of the aqueous dispersion is 0.05 Pa s or greater, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.

17. (Previously presented) The composition according to claim 16, wherein the enteric coated pellets are spherical and have a diameter of less than 1 mm.

18. (Previously presented) The composition according to claim 16, wherein the enteric coated pellets are spherical and have a diameter of less than 0.5 mm.

Claim 19 (Canceled)

Claim 20 (Canceled)

Claim 21 (Currently amended) The method according to claim 1 [[or 5]], wherein the amount of proton pump inhibitor compound that is administered is in the range from 0.5 to 20 mg.